Inclusion Criteria:  Risankizumab-Exposed Cohort  US resident. Current pregnancy. Diagnosis of plaque psoriasis. Exposure to risankizumab at any time during pregnancy (at least 1 dose during pregnancy or within 20 weeks prior to conception).  Diseased Comparison Cohort  US resident. Current pregnancy. Diagnosis of plaque psoriasis. Exposure to other medications in the same class or line of therapy as risankizumab (TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitor, and other IL-23 inhibitors) at any time during pregnancy (at least 1 dose during pregnancy or prior to pregnancy within a specified time period based on the product's half-life).  Exclusion Criteria:  Risankizumab-Exposed Cohort  Exposure to other medications in the same class or line of therapy as risankizumab (TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitor, and other IL-23 inhibitors) at any time during pregnancy (at least 1 dose during pregnancy or prior to pregnancy within a specified time period based on the product's half-life). Exposure to known teratogens and/or investigational medications during pregnancy (at least 1 dose during pregnancy or prior to pregnancy within a specified time period based on the product's half-life). Diagnostic prenatal test results known prior to first contact with the registry coordination center (RCC). Inclusion in the analysis population for a prior pregnancy.  Diseased Comparison Cohort  Exposure to risankizumab at any time during pregnancy (at least 1 dose during pregnancy or within 20 weeks prior to conception). Exposure to known teratogens and/or investigational medications during pregnancy (at least 1 dose during pregnancy or prior to pregnancy within a specified time period based on the product's half-life). Diagnostic prenatal test results known prior to first contact with the RCC. Inclusion in the analysis population for a prior pregnancy.